Currently, TKIs of MET, such as crizotinib initially, and more recently capmatinib and tepotinib, have demonstrated clinical efficacy and safety in lung cancer patients with MET exon 14 skipping mutations (17, 18) and MET gene amplification (19). This evidence concerns the gene MET and lung carcinoma.